To compare diagnostic values of CPH-I (Copenhagen Index), SMS (sonographic morphology scores), RMI (risk of malignancy index), and the combination of CPH-I and SMS. This retrospective research involves 143 patients with adnexal masses who were diagnosed and managed in our institution, including 99 cases (69.2%) with benign ovarian disease and 44 cases (30.8%) with ovarian cancer. The baseline characteristics and predictive measurable variables such as patient's age, menstrual status, serum CA125, HE4 results, and ultrasound reports were collected. We compared diagnostic values of CPH-I, SMS, RMI, and the combination of CPH-I and SMS. The area under the curve (AUC) of CPH-I, SMS, CPH-I + SMS, and RMI were 0.932, 0.916, 0.976, and 0.877, respectively. The suggested cutoffs of CPH-I, SMS, CPH-I + SMS, and RMI were 12.42%, 6.5, 0.6506, and 173.55, respectively. Moreover, the sensitivities in the prediction of ovarian cancer were 81.8%, 79.5%, 93.2%, and 84.1%, and the specificities were 96.0%, 89.9%, 93.9%, and 89.9%, respectively. The combination showed remarkably higher sensitivity in the differential diagnosis than other three predictive modalities, and higher specificity than SMS and RMI reported. It suggested that the performance of the combined modalities provides a more accurate methods in the preoperative diagnosis and differentiation of adnexal masses in women with high risk factors. However, the sensitivity, specificity, and positive predictive value of the combination of CPH-I and SMS require prospective evaluation and validation in a randomized, controlled trial settings in the future.
Introduction
According to the American Cancer Society, ovarian cancer is one of the most common malignancies in the female reproductive system, and mortality of ovarian cancer ranks the first in all of the neoplasms in postmenopausal women. In 2017, 22,440 new cases were diagnosed with ovarian cancer, and 14,080 deaths in the USA [1] . In 2015, on average, about 52.1 out of every 100,000 women had ovarian cancer, of which an average of 22.1 deaths per 100,000 women were counted in China [2] . However, the progression of ovarian cancer is insidious, lacking typical early clinical symptoms and early effective diagnosis methods, so most of the patients with ovarian cancer are diagnosed at advanced stage when they first visit. Late-stage presentation has a 5-year relative survival rate of 29%, by contrast with 92% for early-stage disease [3] . What is worse, although the majority of patients achieve complete clinical response after initial cytoreductive surgery and platinum-based chemotherapy, approximately 80% of patients will recur [4] , so the early diagnosis and timely treatment of ovarian cancer are of great significance for the survival of the patients.
The risk of malignancy index (RMI) is proposed by Jacobs; it is a diagnostic model based on serum CA125 level, ultrasound score, and menopausal status, to predict the risk of epithelial ovarian carcinoma in patients with pelvic masses.
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The sensitivity and specificity of RMI are 85.4% and 96.9%, respectively, when using an RMI cutoff level of 200 [5] .
In 2015, Karlsen launched a study which composed two steps and two separate studies, training study and validation study. By training study, they developed a new predictive modality called Copenhagen Index (CPH-I), which mainly based on these variables serum HE4, CA125, and patient age. Followed by a validation cohort study, the result denotes that CPH-I was highly significant in the discrimination of benign and malignant ovarian disease. The sensitivity and specificity were 95.0% and 78.4%, respectively, in the training cohort, and 82.0% and 88.4% in the validation cohort when the cutoffs were set to 0.070 [6] . In other words, CPH-I performs well compared with the established RMI. They have similar sensitivity and specificity for the discrimination of malignant ovarian cancer from benign masses; however, CPH-I is more convenient for the prediction because it is a predictive model based on biomarkers and clinical information only.
The sonographic morphology scores (SMS) were used as proposed by Finkler et al. [7] , known as the Finkler scoring system, which was used to differentiate benign from malignant ovarian tumors. Therefore, we suspect whether the addition of ultrasound information to CPH-I could have a higher accuracy in the processes of evaluation of assessment when compared with RMI before the interaction of surgery and medical treatment.
Patients and Methods

Patient Selection
All the processing of data collection and analysis were agreed by informed consent of research participants and in accordance with the ethical standards of the institutional committee. Ethical approval was obtained from the ethics committee of the Nanfang Hospital of Southern Medical University. This is a retrospective study which involves 143 patients with adnexal masses who were diagnosed and managed in our institution from January 2016 to December 2017. Inclusion requires that the women over 18 years old were diagnosed as adnexal masses with pathologic outcome and did not receive any intervention with the masses before admission, such as surgery, chemotherapy, radiotherapy, immunity therapy, and Chinese medicine treatment. Women who presented with serious clinical diseases in heart, lung, kidney, liver, or other organs or had a surgery for adnexal mass were excluded in this study. In addition, pregnant woman were not included. The Inclusion and exclusion criteria are listed briefly in Table 1 . Postoperative pathologic results were performed and collected. Pathology data were classified according to the WHO histological criteria [8] and divided into subtypes. A total of 44 ovarian cancer were diagnosed according to the International Federation of Gynecology and Obstetrics (FIGO) classification criteria ( Table 2 ). In our study, the borderline ovarian tumors are included in the malignant group. Moreover, the malignant group also incorporated the case with diagnosis as mixed masses with both benign ovarian tumor and malignant one.
Methods
Information such as patient age, menstrual status, pathological type, serum CA125 (from Siemens), HE4 (from Abbott) was collected, as well as ultrasound reports in the medical record system. All biomarker assays were run according to the manufacturer's package insert instructions. The analytical runs fulfilled the laboratory quality control criteria. Cutoff levels were 35 U/mL for CA125 and 140 pmol/L for HE4. Ultrasound image information was obtained with a GE Voluson E8 ultrasound machine.
The Copenhagen Index (CPH-I) was calculated for each subject using the formulae proposed by Karlsen et al. [6] . It was defined as follows:
The predicted probability (PP) = e (CPH-I) /(1 + e (CPH-I) ) and the risk of malignancy index (RMI) were used as proposed by Jacobs et al. [5] . It was defined as follows: RMI = U * M * (serum CA 125). U = 0 (for ultrasound score of 0) = 1 (for ultrasound score of 1) = 3 (for ultrasound score of 2-5) M = 1 (if premenopausal) = 3 (if postmenopausal) RMI = 200 is used as the cutoff value to distinguish benign and malignant diseases.
Ultrasound reports were scored 1 point for each of the following characteristics: (i) multinodular cyst, (ii) evidence of solid areas, (iii) evidence of metastases, (iv) presence of ascites, and (v) bilateral lesions.
As for the sonographic morphology scores (SMS), it was used as the Finkler scoring system. In this system, lesions were scored with the method shown in Table 3 [7] .
Statistics Methods
Normal distribution data were recorded by median, and comparisons between two groups were performed by t test.
Logistic regression was used to analyze the combining predictor for CPH-I and SMS. The receiver operating characteristic (ROC) curve was traced, and the sensitivity and specificity were calculated. The benign mass group was set as negative control and CPH-I, SMS, and RMI were calculated and compared with the malignancy mass group. The nonparametric Mann-Whitney U test was employed for comparisons of abnormal distribution data. For all statistical analysis, P value less than 0.05 was considered to be of statistical significance, and SPSS 19.0 software (IBM) was used for the statistical analyses. Moreover, we used GraphPad Prism 7 to create the artwork.
Results
Clinical Pathological Types and FIGO Staging of the Patients
As shown in Table 2 , the clinical pathological characteristics of the patients were collected. One hundred forty-three patients were enrolled in the study, and 99 (69.2%) cases were benign ovarian disease. Of the benign cases, 29 (29.3%) were serous, 27 (27.3%) mucinous, 32 (33.3%) mature teratoma, 10 (10.1) mixed masses, and 1 non-classified. Forty-four (30.8%) patients were diagnosed as malignancies, including 32 serous (72.7%) (included 2 cases (4.6%) of serous borderline tumor), 6 mucinous (13.6%) (included 1 case (2.3%) of mucinous borderline tumor), 4 endometrioid (9.1%) (included 1 case (2.3%) of endometrioid carcinoma with endometrioid borderline tumor), 1 mixed masses (2.3%) (the endometrioid carcinoma with serous borderline tumor), and 1 non-classified (2.3%). Among the malignant adnexal masses, 15 (34.1%) cases were diagnosed in early stage (FIGO I and II) and 29 (65.9%) cases with advanced stage (FIGO III and IV).
The Comparison of Tumor Markers CA125, HE4, and Three Predictive Modalities
As shown in Table 4 , epithelial ovarian cancer had higher serum level of HE4 (258.6 pmol/L) and CA125 (349.0 U/ mL) than benign ovarian diseases (HE4 50.1 pmol/L; CA125 14.2 U/mL, respectively). The CPH-I, SMS, and RMI of epithelial ovarian cancer (CPH-I 70.0%; SMS 9.5; RMI 1162.8) are higher than the cutoff suggested by other researchers (CPH-I 7.0%; SMS 7; RMI 200) [5] [6] [7] . Besides that, there was a significant difference between different stage diseases (early stage vs advanced stage) in epithelial ovarian cancer (P < 0.05). According to the subsets of pathology, (Fig. 1 ).
The ROC of CPH-I, SMS, and RMI and the Combination of CPH-I and SMS
ROC was first introduced and conducted in this study to compare the diagnostic values of CPH-I, SMS, RMI, and the combination of CPH-I and SMS (Fig. 2 ; Table 5 ). As seen in Fig. 2 Table 5 ). The combination showed higher sensitivity than other predictive modalities, and higher specificity than SMS and RMI. Those data suggest that CPH-I plus SMS has a more predictive value in the differential diagnosis of epithelial ovarian cancer from benign diseases.
Discussion
Nowadays, there is no efficient method for the early diagnosis of ovarian cancer. In order to find out a more effective predictive model, we have compared the predictive values of CPH-I, SMS (proposed by Finkler et al.), RMI, and the combination (CPH-I plus SMS) in our study. CPH-I, SMS, and RMI are three of reported predictive methods that are used for the early detection of ovarian cancer by several researchers. As a predictive index, CPH-I is calculated which is composed of CA125, HE4, and age of patients who were found with adnexal mass. Karlsen [6] and Yoshida [9] indicated that CPH-I has high AUC for the prediction of ovarian cancer (the AUC of CPH-I is 0.959 and 0.960). However, CPH-I which is a predictive model based on biomarkers and clinical information might only lead to a misdiagnosis when used to differentiate ovarian cancer from benign disease. As a popular routine gynecological exam tool, transvaginal ultrasound could provide about 80% of all the information; sonographic morphological score is a morphological score about ovarian cancer. Studies reported that the sensitivity and specificity of SMS is 85% and 70% [10] . The sensitivities and specificities of the RMI index in our study are similar to the findings of Krascsenits whose sensitivity and specificity were 82.0% Table 4 Comparison of serum levels of CA125 and HE4, and CPH-I, SMS, and RMI among groups Clear cyst and smooth borders or fibroid (ovaries normal), or tubular cyst such as hydrosalpinx 1 Clear cyst with slightly irregular border; cyst with smooth walls but low-level echoes(i.e., endometrioma) 2 Cyst with low-level echoes with slightly irregular border but no nodularity (i.e., endometrioma); clear cyst in postmenopausal patient 3 Equivocal, nonspecific ultrasound appearance: solid ovarian enlargement or small cyst with irregular borders and internal echoes (hemorrhagic cyst or benign ovarian tumor)
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Multiseptated or irregular cystic mass consistent in appearance with ovarian tumor (7 = less nodularity, 8-9 = more nodularity) 7-9 Pelvic mass as above, with ascites 10 *1 = benign; 10 = malignant and 85.1%, respectively [11] . For postmenopausal women, RMI's sensitivity was 90.9%, but showed low sensitivity.
The combination modality of this study was that the methods were more integrated by the combination of SMS and CPH-I; this combination of models includes not only age and tumor markers but also related information on ultrasound morphological score. It is convenient to get the baseline clinical data of ovarian cancer patients and compute the cutoff values in a relative simple setting, but not complicated calculation. Our study also showed that the combination has the highest AUC and markedly higher sensitivity and the specificity than other three methods, which suggests that it provides a pivotal way to diagnose ovarian cancer early.
Our study still has some limitations. First, there were only 143 patients involved in this study and most of them are from a single institution in the southern China region and the genetic backgrounds are almost identical, so regional or ethnic bias is therefore inevitable. Second, although the results shown in our study are similar to those reported in the forms of SMS, CPH-I, and RMI by other researchers, the validity of the combination still needs to be further studied and validated in randomized controlled trials (RCT) in multi-center institutions in different regions or ethnicities background. All the patients recruited in this study were diagnosed with adnexal masses by ultrasonography and were confirmed by postoperative pathology, and the patients' stratifications were not performed according to the high-risk factors. It might lower the "screening" prediction of the combination methods, and further shunting of the patients in lower-risk populations should be verified in the following studies. It is the right way to achieve the early prediction and diagnosis values and provide treatment options for the ovarian cancer patients, and then improve the overall survival of the patients in the future. Overall, the combination of CPH-I and SMS showed remarkably higher efficacy in the differential diagnosis of ovarian cancer than other three predictive modalities in women with adnexal masses in this study. Patient's age, serum CA125, HE4 levels, and ultrasound information are all easily obtained clinically, so the combination of CPH and SMS has great operability and repeatability, and is a cost-effective way. However, the combination still needs further to be evaluated and validated prospectively in the population with adnexal masses.
Conclusion
The combination showed remarkably higher sensitivity in the differential diagnosis than other three predictive modalities, and higher specificity than SMS and RMI reported. It suggested that the performances of the combined modalities provide more accurate methods in the preoperative diagnosis and differentiation of adnexal masses in women with high risk factors. However, the sensitivity, specificity, and positive predictive value of the combination of CPH-I and SMS require prospective evaluation and validation in a randomized, controlled trial settings in the future. 
